- Five-Year Business Highlights
- Quarter Business Highlights
Principal Financial Data
Fiscal year (millions of yen) |
ending March 2023/Q1 (IFRS) | ending March 2023/Q1~2 (IFRS) | ending March 2023/Q1~3 (IFRS) | ending March 2023/Q1~4 (IFRS) | ending March 2024/Q1 (IFRS) | ending March 2024/Q1~2 (IFRS) | ending March 2024/Q1~3 (IFRS) | ending March 2024/Q1~4 (IFRS) | ending March 2025/Year Ended (forecast) (IFRS) |
---|---|---|---|---|---|---|---|---|---|
Sales revenue | 35,619 | 71,136 | 109,919 | 144,175 | 37,012 | 73,314 | 112,728 | 148,255 | 150,000 |
Pharmaceuticals | 30,407 | 60,499 | 93,095 | 121,988 | 30,870 | 60,988 | 94,606 | 125,105 | 128,500 |
Functional food | 5,211 | 10,637 | 16,824 | 22,187 | 6,142 | 12,325 | 18,121 | 23,150 | 21,500 |
Operating income | 10,276 | 19,161 | 27,987 | 30,049 | 11,163 | 20,878 | 30,450 | 33,295 | 31,000 |
Net income attributable to owners of the parent | 8,249 | 15,222 | 22,674 | 22,812 | 8,749 | 16,176 | 24,002 | 25,851 | 24,500 |
Depreciation and amortization | - | 2,388 | - | 5,041 | - | 2,462 | - | 5,023 | 5,800 |
Capital investment | - | 3,569 | - | 7,982 | - | 3,358 | - | 6,921 | 5,500 |
R&D expenses | 4,738 | 9,691 | 15,135 | 24,135 | 5,911 | 12,517 | 19,500 | 31,676 | 31,500 |
Total assets | 219,684 | 225,374 | 231,876 | 237,451 | 237,408 | 249,499 | 247,830 | 263,404 | |
Total equity | 185,227 | 191,503 | 195,968 | 195,933 | 202,799 | 211,774 | 215,316 | 220,534 |
Sales revenue
Operating income
Net income attributable to owners of the parent
R&D expenses
Cash Flows
Fiscal year (millions of yen) |
ending March 2023/Q1 (IFRS) | ending March 2023/Q1~2 (IFRS) | ending March 2023/Q1~3 (IFRS) | ending March 2023/Q1~4 (IFRS) | ending March 2024/Q1 (IFRS) | ending March 2024/Q1~2 (IFRS) | ending March 2024/Q1~3 (IFRS) | ending March 2024/Q1~4 (IFRS) |
---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | 3,872 | 12,817 | 12,618 | 26,170 | 526 | 7,938 | 8,126 | 16,289 |
Cash flow from investing activities | △1,566 | △5,882 | △9,421 | △17,631 | △2,060 | △1,693 | △2,654 | △9,921 |
Cash flow from financing activities | △4,289 | △4,911 | △8,922 | △9,605 | △4,047 | △4,685 | △9,046 | △9,719 |